These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 21476058)
21. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673 [TBL] [Abstract][Full Text] [Related]
22. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503 [TBL] [Abstract][Full Text] [Related]
23. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Kong G; Johnston V; Ramdave S; Lau E; Rischin D; Hicks RJ Cancer Biother Radiopharm; 2009 Oct; 24(5):527-33. PubMed ID: 19877882 [TBL] [Abstract][Full Text] [Related]
24. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R; J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057 [TBL] [Abstract][Full Text] [Related]
25. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Al-Efraij K; Aljama MA; Kennecke HF Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756 [TBL] [Abstract][Full Text] [Related]
26. Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors. Saglam S; Hacisahinogullari H; Ozturk N; Kapran Y; Gulluoglu M; Turkmen C; Adalet I; Orhan Bilge A; Cem Balci N J BUON; 2015; 20(5):1201-5. PubMed ID: 26537065 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial. Longo F; De Filippis L; Zivi A; Vitolo D; Del Signore E; Gori B; Diso D; Anile M; Venuta F; De Giacomo T; Coloni CF Am J Clin Oncol; 2012 Apr; 35(2):105-9. PubMed ID: 21325939 [TBL] [Abstract][Full Text] [Related]
28. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001 [TBL] [Abstract][Full Text] [Related]
29. Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Caplin ME; Mielcarek W; Buscombe JR; Jones AL; Croasdale PL; Cooper MS; Burroughs AK; Hilson AW Nucl Med Commun; 2000 Jan; 21(1):97-102. PubMed ID: 10717909 [TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964 [TBL] [Abstract][Full Text] [Related]
35. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997 [TBL] [Abstract][Full Text] [Related]
36. Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. Davis LM; Nicou N; Martin W; Corcoran B; Mulholland N; Srirajaskanthan R; Ramage J; Wendler O; Vivian G Nucl Med Commun; 2020 Jun; 41(6):575-581. PubMed ID: 32371675 [TBL] [Abstract][Full Text] [Related]
37. Cyto-reduction of neuroendocrine tumours using Sandostatin LAR in combination with Infergen: results of a case series. Wang HS; Oh DS; Ohning GV; Pisegna JR J Pharm Pharmacol; 2006 Dec; 58(12):1623-8. PubMed ID: 17331326 [TBL] [Abstract][Full Text] [Related]
38. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Shen C; Shih YC; Xu Y; Yao JC Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553 [TBL] [Abstract][Full Text] [Related]
39. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Bushnell D; O'Dorisio T; Menda Y; Carlisle T; Zehr P; Connolly M; Karwal M; Miller S; Parker S; Bouterfa H J Nucl Med; 2003 Oct; 44(10):1556-60. PubMed ID: 14530466 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Delpassand ES; Sims-Mourtada J; Saso H; Azhdarinia A; Ashoori F; Torabi F; Espenan G; Moore WH; Woltering E; Anthony L Cancer Biother Radiopharm; 2008 Jun; 23(3):292-300. PubMed ID: 18593362 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]